Resolution following streptokinase therapy was most noticeable in patients treated shortly after a single embolic episode, and was least marked in those with recurrent embolism complicated by associated cardiac or pulmonary disease. Of the four patients who failed to improve, two died and two had pulmonary embolectomy and survived.
Introduction
The dissolution of thrombi by enzymatic means has been investigated clinically and experimentally for a number of years. Experimentally it has been shown that the plasminogen activators, streptokinase and urokinase, accelerate resolution of pulmonary emboli in animals (Browse and James, 1964; Genton and Wolf, 1967a) . Angiographic improvement has also been documented after thrombolytic therapy in patients with severe pulmonary embolism (Hirsh et al., 1967; Sasahara et al., 1967; Sautter et al., 1967; Tow et al., 1967) . However, further investigations are required before the place of thrombolytic therapy in the management of acute major pulmonary embolism can be clearly defined. The evaluation of this form of therapy in acute pulmonary embolism demands consideration of the following questions: (1) Is it technically feasible ? (2) Does it accelerate dissolution of the embolus and improve immediate survival ? (3) Does it reduce the incidence and severity of late sequelae ?
The purpose of this communication is to report the clinical, angiographic, and haemodynamic findings before, during, and after streptokinase therapy in 18 patients with major pulmonary embolism. In addition, angiographic and haemodynamic changes after 24 hours of heparin administration are recorded in three patients. * (Tables  I and II) . Five had associated cardiac or respiratory disease (subsequently referred to as "complicated ") ( Table I ). All were breathless and had clinical and haemodynamic evidence of pulmonary hypertension and right heart failure. Four required isoprenaline (isoproterenol U.S.P.) infusion to maintain an adequate circulation. All angiograms showed filling defects in the major pulmonary vessels with severe obstruction on both sides. The cardiac index, calculated in 10 cases, ranged from 1.2 to 4.3 litres/min./sq. m. and was less than 2.5 1. in four patients (normal range 2.5 to 3.5 1). An (Hirsh et al., 1967) , the following tests being used: thrombin clotting-time, prothrombin time, kaolin partial thromboplastin time, euglobulin lysis time, fibrin plate assay, plasma fibrinogen assay, and plasma plasminogen assay.
Brachial and pulmonary arterial pressures were recorded serially. Cardiac output was measured by the indicator dilution principle with indocyanine green injected into the pulmonary artery and sampled from the brachial artery through an indwelling Teflon catheter, and pulmonary angiograms were obtained with a rapid film changer (4-6 films per second). Lung function tests included arterial blood gas analysis by means of an Instrumentation Laboratories triple electrode system; mixed expiratory gas CO 2was analysed by the same system and the alveolar-arterial oxygen tension difference (A-a Po2) and percentage wasted ventilation (VD/VT) calculated (Comroe et al., 1962) .
Treatment.-Heparin 10,000 units was given intravenously when the clinical diagnosis of major pulmonary embolism was made, and the pulmonary angiogram was performed as soon as possible. The loading dose of streptokinase given over a period of 30 minutes was determined by the streptokinase resistance test, and this was followed by a maintenance dose of approxiBRsSs MEDICAL JOURNAL mately 100,000 units per hour. Treatment with heparin was continued throughout the streptokinase infusion and the dosage regulated to maintain the kaolin partial thromboplastin time one and a half to three times normal (normal 35-45 seconds). Heparin by intravenous infusion was continued after streptokinase had been stopped for a minimum of 10 days or until the patient was fully ambulant. Oral anticoagulants were begun about four days before stopping heparin, and were continued for a period of six months (O'Sullivan et al., 1968) . Pulmonary embolectomy was performed in two patients under cardiopulmonary bypass.
Results

Observations on Heparin Therapy
Of the 18 patients treated with streptokinase, 11 were given heparin for 24 hours or more before streptokinase was started. In four, heparin therapy as judged by clotting-time control was (4) 9 (12) 2 (4) 9 (12) 2 (5) 10 (15) 12 (15) 9 (14) 9 (13) 10 (12) 9 (12) 2 (3) 0 (4) 3 (7) 9 (13) 7 (11) 1 (4) 5 (14) 4 (7) 4 (10) 17 (21 Sixteen patients had angiograms repeated 24 hours after streptokinase therapy. Eight showed marked improvement, three moderate improvement, two slight improvement, two no significant change, and one had a recurrent embolus (Table I) . Representative angiograms are shown in Figs. 3, 4, and 5 (Special Plate) . It is noteworthy that the most pronounced improvement occurred in the first 24 hours (Figs. 4 and 5 ). Angiographic and haemodynamic improvement noted during or after 24 hours of streptokinase therapy appeared to be less marked in patients with either associated cardiopulmonary disease (referred to as complicated pulmonary embolism) or with clinical evidence of recurrent emboli (Tables I and II) . Thus the four patients with recent uncomplicated pulmonary embolism who were treated with streptokinase for 24 hours showed marked angiographic and haemodynamic improvement. In contrast, of the 12 patients with either associated cardiopulmonary disease or recurrent pulmonary embolism restudied at 24 hours, only five showed marked improvement while two showed moderate improvement, two slight improvement, two no change, and in one there was a recurrent embolus.
In both the acute and recurrent groups the fall in mean pulmonary artery pressure following streptokinase was striking and highly significant (P=0.05 in the acute group and P<0.01 in the recurrent group). It is of interest that when the patients were divided into those with complicating associated cardiac or pulmonary disease and those without, the fall in mean pressure in the complicated group was not significant (0.2<P<0.3). In the seven patients in whom the index of pulmonary vascular obstruction was measured before and after therapy there was a highly significant fall from 10.8 to 7.4 (0.01<P<0.001). In contrast in the two patients in whom the index was calculated before and after heparin (Cases 2 and 3) there was a slight fall in one and a slight rise in the other.
Clinical, Haemodynamic, and Lung Function Follow-up
Fifteen of the 18 patients were alive and free of symptoms 6 weeks to 12 months after treatment with streptokinase. These included the two patients who required pulmonary embolectomy (Cases 1 and 14). Eight patients (Cases 2, 3, 5, 9, 10, 11, 12, and 15) who survived and were treated with streptokinase without pulmonary embolectomy had follow-up haemodynamic studies three days to one month after beginning streptokinase therapy. Six showed an insignificant rise in pulmonary artery pressure (Cases 2, 5, 9, 10, 12, and 15). Two patients had raised pulmonary arterial pressure four days to three weeks after streptokinase treatment (Cases 3 and 11). One of these (Case 3) had streptokinase for only 11 hours and the other had the investigations repeated only four days after starting streptokinase therapy.
Follow-up lung function tests, which included A-a Po.
difference and VD/VT at rest in nine patients (Cases 1, 2, 3, 4, 7, 9, 10, 11, and 12) and on effort in four (Cases 1, 2, 4, and 12), were performed one to eight months after streptokinase therapy. The VD/VT was normal in all at rest, and in three of the four tested during effort no increase was detected. A mild rise of the A-a Po. difference at rest was found in four of these nine patients (Cases 1, 4, 7, and 10). These results represent a marked improvement on the results of pulmonary function tests performed on diagnosis.
Complications
Local bleeding from the site of brachial arterial puncture occurred in five patients. More serious bleeding occurred in three patients. One (Case 14) developed cardiac tamponade (diagnosed at pulmonary embolectomy), which was caused by right ventricular perforation during the initial cardiac catheterization. Another (Case 5) developed a large haematoma of the buttock after an inadvertent intramuscular injection, and in the third (Case 3) streptokinase therapy had to be stopped because of bleeding from the site of brachial artery puncture. In addition an unexplained fall in haematocrit of up to 10% occurred in three other patients (Cases 2, 9, and 12). Mild asymptomatic fever of up to 38.50 C. followed streptokinase therapy in eight patients. This responded to intravenous corticosteroids. Two other patients developed a temperature of 390 C. immediately after the second pulmonary angiogram; this may also have been partly due to streptokinase therapy.
Discussion
The majority of pulmonary embolism episodes do not cause haemodynamic changes severe enough to give rise to symptoms, and are recognized clinically only when they produce features of pulmonary infarction. Untreated patients with these minor embolic episodes may die from further embolism or from propagation of thrombi from the initial embolus. These sequelae are considerably reduced by adequate heparin therapy (Thomas, 1965 Though spontaneous resolution of heparin-treated massive pulmonary embolism has been described in man (Emanuel et al., 1966 ; Fred et al., 1966) , the rate of resolution in the first 24 to 48 hours after the episode is not known. However, the findings reported by Chait et al. (1967) suggest that angiographically demonstrable spontaneous resolution in the first 24 hours is relatively uncommon. Thus these authors found that only 5 out of 20 patients with major pulmonary embolism showed significant resolution seven or more days after the initial episode. Furthermore, in the present series the only three patients studied after 24 hours of heparin treatment showed no angiographic improvement, and there was a fall in pulmonary arterial pressure in one.
Our experience with streptokinase in the treatment of acute major pulmonary embolism has been encouraging. Thus all patients in the series had major pulmonary embolism severe enough to be considered forpulmonary embolectomy; yet only one failed to survive the initial treatment period and two others subsequently died seven and nine days after streptokinase therapy. All three patients had complicating cardiac disease, and one died from causes unrelated to pulmonary embolism. Two patients developed complications and required pulmonary embolectomy; it is possible that thrombolytic therapy may have contributed to these complications. Thus in one patient the operative findings suggested that the cardiac arrest which occurred during streptokinase therapy may have been caused by obstruction consequent on fragmentation of the bifurcation embolus, and in the other streptokinase may have been responsible, at least in part, for the recurrent embolus.
Eleven of the remaining 13 patients were restudied 24 hours after streptokinase therapy. Eight showed marked improvement and three moderate improvement at 24 hours. In most patients who had further angiograms at 48 or 72 hours it was evident that maximum improvement had occurred in the first 24 hours (Fig. 4) .
It is of interest that only two patients treated with streptokinase showed no improvement angiographically at 24 hours and that both had organized emboli at necropsy. As might be predicted from other investigations (Johnson and McCarty, 1959; Genton and Wolf, 1967b) (Schmutzler et al., 1966 -Verstraete et al., 1966 and contrasts with the severe reactions described with earlier preparations of streptokinase (Tillett et al., 1955) .
The results of this and other studies suggest that thrombolytic therapy is a practical form of treatment in patients with acute major pulmonary embolism (Hirsh et al., 1967; Sasahara et al., 1967; Sautter et al., 1967; Tow et at., 1967 (Hollister and Cull, 1956; Orell, 1962 months later she developed headaches, dizziness, and pounding in the head, and stopped taking indomethacin. She was found to be anaemic (haemoglobin 60%), and a barium meal examination revealed a prepyloric ulcer. She had had no indigestion at any time. One month after stopping indomethacin she was asymptomatic, and a barium meal examination showed complete healing of the ulcer. She remained symptom-free six months later.
Case 2
A 48-year-old shopkeeper had had rheumatoid arthritis since 1964. He was started on oral indomethacin in May 1965, and continued taking 150-250 mg. daily for two years. In May 1967 he was admitted to hospital as an emergency case, having vomited a large amount of blood. One month previously he had developed epigastric pain, but had been unable to reduce the dosage Gi. indomethacin because of increasing stiffness. He had had no indigestion before this time. A barium meal examination showed a shallow prepyloric ulcer. He was given no further indomethacin by mouth, but was started on suppositories (100 mg. twice daily). A barium meal examination one month later showed only a very shallow crater. A further barium meal examination in September 1967 showed the ulcer to be larger. The appearance wa-said to be suspicious of malignancy. Indomethacin suppositories were withdrawn, and three months later the ulcer was completely healed. He remained symptom-free six months later.
Case 3
A 61-year-old electrical inspector was admitted to hospital in September 1965, having had rheumatoid arthritis for 14 months.
